Currently, NeuroOne Medical Technologies Corp [NMTC] is trading at $1.08, down -5.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NMTC shares have gain 30.77% over the last week, with a monthly amount glided 83.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroOne Medical Technologies Corp [NASDAQ: NMTC] stock has seen the most recent analyst activity on March 29, 2022, when Craig Hallum downgraded its rating to a Hold and also revised its price target to $2 from $6.
This stock has fluctuated between a low of $0.55 and a high of $1.59 over the last 52 weeks. NeuroOne Medical Technologies Corp [NASDAQ: NMTC] shares were valued at $1.08 at the most recent close of the market.
Analyzing the NMTC fundamentals
Trailing Twelve Months sales for NeuroOne Medical Technologies Corp [NASDAQ:NMTC] were 3.45M which represents -63.29% decline. Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -3.44%, Pretax Profit Margin comes in at -3.57%, and Net Profit Margin reading is -3.57%. To continue investigating profitability, this company’s Return on Assets is posted at -2.29, Equity is -4.07 and Total Capital is -3.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9973 points at the first support level, and at 0.9147 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1413, and for the 2nd resistance point, it is at 1.2027.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NeuroOne Medical Technologies Corp [NASDAQ:NMTC] is 2.03. Further, the Quick Ratio stands at 0.84, while the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 9.65, the price to book ratio is 40.49.
Transactions by insiders
Recent insider trading involved Christianson Mark, Business Development Director, that happened on Jun 06 ’24 when 2189.0 shares were sold. Business Development Director, Christianson Mark completed a deal on Jun 05 ’24 to sell 25800.0 shares.
